ストックスクリーナーアプリを入手
8.74
7.27%
-0.69
Phathom Pharmaceuticals Inc (PHAT) 最新ニュース
PHAT Stock Falls 7% As Leerink Sees Little Near-Term Upside — CEO Plays Down Upcoming Rival - Yahoo Finance
PHAT Initiates Coverage On Leerink Partners -- Rating Set to Market Perform - GuruFocus
Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case (NASDAQ:PHAT) - Seeking Alpha
Phathom at Cantor conference: growth, access and new uses - Investing.com
PHAT Looks 63.2% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Phathom Pharmaceuticals Stock Price Forecast. Should You Buy PHAT? - StockInvest.us
PHAT stock holds near 9 dollars as Q2 loss narrows and revenue rises - AD HOC NEWS
PHAT stock trades quietly as Phathom Pharmaceuticals prepares next data releases - AD HOC NEWS
Price-Driven Insight from (PHAT) for Rule-Based Strategy - Stock Traders Daily
Phathom Pharmaceuticals to present at 2026 Cantor and HCWCO investment conferences - Traders Union
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
4,525,129 Shares in Phathom Pharmaceuticals, Inc. $PHAT Acquired by BlackRock Inc. - MarketBeat
Phathom Pharmaceuticals Inc. (PHAT) Key Financial Ratios – Valuation, Profitability & More - Value Research
Phathom Pharmaceuticals Inc. (PHAT) Peer Comparison – Compare with Others - Value Research
Hsbc Holdings PLC Purchases Shares of 709,695 Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom (PHAT) Today: Moves 3.14% Higher to $8.87 in the Latest Session; Current Setup: the Session Ends Within the Reported Technical Boundaries at the CloseFibonacci Entry Signals - siam.in
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 8.2%What's Next? - MarketBeat
PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff? - Stocktwits
3,496,808 Shares in Phathom Pharmaceuticals, Inc. $PHAT Acquired by Carlyle Group Inc. - MarketBeat
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and BioMarin Pharmaceutical (BMRN) - The Globe and Mail
PHAT Maintains Overweight Rating -- Price Target Lowered to $14 - GuruFocus
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Phathom Pharmaceuticals (PHAT) Advances 4.36% to $9.58, Approaches Key Resistance at $10.06MESA MA - vinanet.vn
Phathom Pharmaceuticals (PHAT) Stock Sees Modest Fair Value Cut After Analyst Target Cuts - Yahoo Finance
Phathom Pharmaceuticals, Inc. (PHAT) Investigation: Bronstein, Ge - The National Law Review
Phathom Pharmaceuticals, Inc.: Target Price Consensus and Analysts Recommendations | PHAT | US71722W1071 - marketscreener.com
PHAT Holds Near $9.18 as Phathom Pharmaceuticals Consolidates Within Key Trading RangeStop Hunt - dars.gov.et
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Shareholders to Connect - ACCESS Newswire
Why (PHAT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Hennion & Walsh Asset Management Inc. Has $3.55 Million Stake in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals (PHAT) Edges Higher at $8.57: Support Holds as Resistance LoomsTriangle Correction - dars.gov.et
Phathom Pharmaceuticals, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Phathom Pharmaceuti - The National Law Review
Renaissance Technologies LLC Acquires New Holdings in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals, Inc. (PHAT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Phathom Pharmaceuticals, Inc. (PHAT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
GYRE Stock Price and Chart — NASDAQ:GYRE - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Phathom Pharmaceuticals, Inc. (PHAT) Investors to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Investors to Reach Out - ACCESS Newswire
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 5.5%Here's Why - MarketBeat
Levi & Korsinsky Notifies Investors of Pending - GlobeNewswire
PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT) - Business Wire
Weekly Recap: Q2 revenue surge and Investigation into NASDAQ:PHAT guidance claim - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Phathom Pharmaceuticals, Inc. (PHAT) And Encourages Stockholders to Reach Out - ACCESS Newswire
925,000 Shares in Phathom Pharmaceuticals, Inc. $PHAT Purchased by Perceptive Advisors LLC - MarketBeat
Phathom Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:PHAT) 2026-08-01 - Seeking Alpha
PHAT Reiterated by HC Wainwright & Co. -- Price Target Maintained at $26 - GuruFocus
PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals - Morningstar
Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Announces Target Price $20 - Moomoo
Raymond James Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Cuts Target Price to $21 - Moomoo
Phathom Pharmaceuticals (PHAT) Stock Slides Despite Cash Profit Breakthrough - webull.com
Phathom Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Phathom Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
Guggenheim cuts Phathom Pharmaceuticals price target on guidance reduction By Investing.com - Investing.com Canada
Earnings call transcript: Phathom posts Q2 2026 revenue beat, shares fall premarket - Investing.com Canada
Phathom Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Phathom Pharmaceuticals Q2 2026 revenue surges as year-over-year growth accelerates - Traders Union
Phathom Q2 Revenue Jumps 88% to $74.3 Million - Quiver Quantitative
Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update - globenewswire.com
Phathom Pharmaceuticals Q2 Results: Sales surge 88% YoY - scanx.trade
BlackRock (PHAT) discloses 4.38M-share passive stake in Pharmaceuticals Inc - stocktitan.net
625,000 Shares in Phathom Pharmaceuticals, Inc. $PHAT Purchased by EcoR1 Capital LLC - MarketBeat
PHAT|Phathom Pharmaceuticals Inc|Price:11.950|Chg%:+0.510 - TradingKey
Phathom Pharmaceuticals Inc - TradingKey
Phathom Pharmaceuticals Inc (PHAT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SummitTX Capital L.P. Purchases 478,065 Shares of Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals Inc (PHAT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Phathom Pharmaceuticals Inc (PHAT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Phathom Pharmaceuticals Inc (PHAT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
0.41%
3.85%
大文字化:
|
ボリューム (24 時間):